| Lizenz: Creative Commons Namensnennung 4.0 International PDF - Veröffentlichte Version (1MB) |
- URN zum Zitieren dieses Dokuments:
- urn:nbn:de:bvb:355-epub-778436
- DOI zum Zitieren dieses Dokuments:
- 10.5283/epub.77843
Zusammenfassung
Recent FDA guidance on adaptive clinical trial designs defines bias as “a systematic tendency for the estimate of treatment effect to deviate from its true value,” and states that it is desirable to obtain and report estimates of treatment effects that reduce or remove this bias. The conventional end-of-trial point estimates of the treatment effects are prone to bias in many adaptive designs, ...

Nur für Besitzer und Autoren: Kontrollseite des Eintrags

Downloadstatistik